行情

CERS

CERS

Cerus Corp
NASDAQ

实时行情|Nasdaq Last Sale

7.25
-0.30
-3.97%
盘后: 7.10 -0.15 -2.07% 18:13 01/15 EST
开盘
7.57
昨收
7.55
最高
7.86
最低
7.23
成交量
219.07万
成交额
--
52周最高
8.87
52周最低
2.710
市值
12.12亿
市盈率(TTM)
-18.2024
分时
5日
1月
3月
1年
5年
新闻
财报
公告
公司事件
分析
简况
Apheresis Market with Size, Growth, Analysis, Demand, Outlook - Trends, Opportunities and Forecast
Jan 12, 2021 (Heraldkeepers) -- Overview: The apheresis market is getting significant traction due to the growing emphasis on the specific features of blood...
Heraldkeepers · 6天前
2021年按地区分列的全球Apheres机器市场分析,市场规模和细分市场,产品范围,总收入,到2026年的业务发展和机会
Jan 12, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry" Global “Apheresis Machines Market” 2020...
The Express Wire · 6天前
Cerus Corporation Announces FDA Approval For INTERCEPT Blood System For Cryoprecipitation
Cerus Corporation (NASDAQ:CERS) today announced that the US Food and Drug Administration (FDA) has granted approval of the INTERCEPT Blood System for Cryoprecipitation. The system is used to produce Pathogen Reduced
Benzinga · 2020/11/30 13:34
The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 28)
Benzinga · 2020/10/29 11:30
The Week Ahead In Biotech: Kala FDA Decision, Merck & Pfizer Earnings, Vaccine Updates And IPOs
Biotech stocks posted weekly declines in the week ended Oct. 23, pressured by the broader market decline amid mixed earnings reports and the impasse on fiscal stimulus.
Benzinga · 2020/10/25 18:42
Cerus Corporation Announces Five-Year FDA Contract For Development Of Next Generation Pathogen Reduction Technology To Treat Whole Blood; Contract Value Totals $11.1M
Cerus Corporation (NASDAQ:CERS) announced today it was awarded a five-year contract with the U.S. Food and Drug Administration (FDA) for the development of next-generation compounds to optimize pathogen reduction (PR)
Benzinga · 2020/10/13 12:41
隔夜美股 | 特朗普叫停刺激案谈判 三大指数尾盘急挫收跌逾1%
智通财经网 · 2020/10/06 22:20
隔夜美股 | 特朗普叫停刺激案谈判 三大指数尾盘急挫收跌逾1%
智通财经网 · 2020/10/06 22:20
更多
财务预测
每股收益每股净资产每股现金流
实际值(美元)
预测值(美元)
利润表更多
净利润营业总收入营业利润
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流投资现金流筹资现金流
经营现金流(美元)
同比(%)
了解CERS最新的财务预测,通过CERS每股收益,每股净资产,每股现金流等数据分析Cerus Corp近期的经营情况,然后做出明智的投资选择。
分析师评级

5位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测CERS价格均价为9.30,最高价位10.00,最低价为8.00。
EPS
机构持股
总机构数: 242
机构持股: 1.52亿
持股比例: 91.03%
总股本: 1.67亿
类型机构数股数
增持
52
1,147.70万
建仓
44
-161.53万
减持
51
814.90万
平仓
0
0
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
医疗设备、用品及经销
+0.03%
医疗设备和用品
+0.12%
高管信息
Chairman/Director
Daniel Swisher
Chief Executive Officer/President/Director
William Greenman
Chief Financial Officer/Vice President - Finance
Kevin Green
Chief Operating Officer
Vivek Jayaraman
Senior Vice President
Carol Moore
Chief Scientific Officer
Laurence Corash
Other
Richard Benjamin
Other
Chrystal Menard
Independent Director
Timothy Anderson
Independent Director
Eric Bjerkholt
Independent Director
Timothy Moore
Independent Director
Jami Nachtsheim
Independent Director
Gail Schulze
Independent Director
Frank Witney
Independent Director
Franklin Witney
  • 分红
  • 拆股
  • 内部人交易
暂无数据
注册即可获得3个月
免费美股Level2深度行情
(Nasdaq Totalview)
立即领取
CERS 简况
Cerus Corporation主要提供生物医药产品。该公司开发和商业化用于确保血液安全的INTERCEPT血液系统。该公司通过血液安全部门运营。其INTERCEPT血液系统是基于控制生物复制的技术研发的,旨在减少捐献的血液成分(用于输血的血源)中的血源性病原体。INTERCEPT血液系统旨在靶向血源性病原体并使血源性病原体失去活性,同时保持血小板、血浆和红细胞等输血产品的治疗特性。这些血源性病原体包括病毒(人类免疫缺陷病毒(HIV)、西尼罗河病毒、严重急性呼吸综合症(SARS)病毒,以及乙型和丙型肝炎病毒等)、细菌和寄生虫以及有害的白细胞等。该公司的INTERCEPT血液系统用于确保血液成分的安全,包括血浆、血小板和红细胞。
展开
热门股票
代码
价格
涨跌幅

微牛提供Cerus Corporation(NASDAQ-CERS)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的CERS股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CERS股票基本功能。